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Edited by Jesus AvilaAbstract Drosophila PTEN (dPTEN) plays indispensable roles
in the development of Drosophila melanogaster by controlling
cell size and number. Although three potential spliced forms of
dPTEN have been isolated, functional distinction among these
forms remains elusive. In this study, we demonstrate that all
spliced forms of dPTEN dephosphorylate phosphatidylinositol
3,4,5-trisphosphate (PI(3,4,5)P3); however, PI(3,4,5)P3-depen-
dent activation of Drosophila Akt is suppressed speciﬁcally by
one of three spliced forms, dPTEN3. Further, dPTEN3
dramatically changes its expression during the Drosophila
development, while the other forms are expressed throughout
the development. Our results suggest that dPTEN3 is the
predominant spliced form that participates in PI(3,4,5)P3-
mediated signaling pathways.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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PTEN has been originally identiﬁed as a tumor suppressor
gene, which is mutated in a number of human tumors [1,2].
The following studies have unveiled that human PTEN
dephosphorylates the lipid second messenger, phosphatidyl-
inositol 3,4,5-trisphosphate (PI(3,4,5)P3), which is produced
by phosphatidylinositol 3-kinase (PI3K) upon growth factor
stimulation [3]. Therefore, PTEN antagonizes PI3K actions,* Corresponding author. Fax: +81-3-3823-5284.
E-mail address: tmaehama@rinshoken.or.jp (T. Maehama).
Abbreviations: dPTEN, Drosophila PTEN; PI(3,4,5)P3, phosphatidyl-
inositol 3,4,5-trisphosphate; PI(3,4)P2, phosphatidylinositol 3,4-bis-
phosphate; PI(3)P, phosphatidylinositol 3-phosphate; PI3K,
phosphatidylinositol 3-kinase; SDS, sodium dodecyl sulfate; PAGE,
polyacrylamide gel electrophoresis; GFP, green ﬂuorescent protein;
GST, glutathione S-transferase
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doi:10.1016/j.febslet.2004.03.074such as promoting cell proliferation and migration and
preventing cells from apoptosis [4–6]. Bioinformatic ap-
proaches have shown that PTEN is evolutionary conserved
in a wide variety of species, from yeast to mammals. Genetic
studies in model organisms have revealed that these PTEN
orthologs also fundamentally antagonize PI3K actions [7–
13].
Drosophila PTEN (dPTEN) plays indispensable roles in
the development of the fruit ﬂy, Drosophila melanogaster [8–
10]. Homozygous mutation in the coding region of dPTEN
results in embryonic lethality and ubiquitous overexpression
of dPTEN in the ﬂy also exhibits lethality. In mosaic Dro-
sophila ﬂies, dPTEN cells proliferate faster than their
heterozygous siblings, resulting in increased cell size and
organ size [8–10]. On the other hand, organ-speciﬁc over-
expression of dPTEN results in opposite phenotype, as
shown by reduced organ size [8–11]. The phenotypes from
the loss of dPTEN function are suppressed by a mutation in
the PI(3,4,5)P3 target, Drosophila Akt (dAkt) [11,14]; in
addition, the overexpression of dPTEN suppresses the
phenotypes induced by the overexpression of Drosophila
PI3K (dp110) or its upstream activator, Inr [8–10]. These
observations indicate that dPTEN counteracts signaling
downstream of the dp110 to control cell growth and pro-
liferation as human PTEN does; however, no biochemical
studies on dPTEN have been yet provided, therefore un-
derlying biochemistry of dPTEN actions still remains poorly
understood. Further, at least three alternatively spliced
forms of dPTEN have been identiﬁed, varying their extended
carboxyl termini [15]; however, distinction of these potential
spliced variants in their functions and biochemical properties
remains unknown.
In this study, we employ biochemical approaches to under-
stand the molecular functions of three dPTEN-spliced vari-
ants, and we demonstrate that dPTEN3, among these variants,
functions as a negative regulator for a dp110-mediated signal
by dephosphorylating PI(3,4,5)P3, while the other forms do
not. In addition, we also demonstrate that the expression of
dPTEN3 is ﬁrmly regulated during the development of the
Drosophila.ation of European Biochemical Societies.
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2.1. Plasmids
Complementary DNAs encoding dPTEN spliced variants
(dPTEN1–3) were ampliﬁed by RT-PCR using RNA isolated from
Schneider-2 cells and cloned into pGEX-6P1 (Amersham Pharmacia)
to create dPTEN1/pGEX, dPTEN2/pGEX, and dPTEN3/pGEX.
Site-directed mutagenesis, to substitute glycine-135 (GGA) to glu-
tamic acid (GAA), was carried out with a PCR-based strategy using
dPTEN2/pGEX as the template. In order to generate Drosophila
expression vector, pDEX, the promoter region of Drosophila actin
5C was ampliﬁed by PCR from Schneider-2 cell genomic DNA and
subcloned into SacII site of pTRE (Clontech). The cDNA encoding
full-length dAkt was ampliﬁed by RT-PCR using RNA isolated
from Schneider-2 cells. The sequence encoding the FLAG epitope
tag was included in the forward primer. The FLAG-dAkt cDNA
insert was subcloned into pDEX to produce FLAG-dAkt/pDEX. To
create N-terminally green ﬂuorescent protein (GFP)-tagged dPTEN
expression vectors, pDEX-GFP, dPTEN1/pDEX-GFP, dPTEN2/
pDEX-GFP, and dPTEN3/pDEX-GFP, dPTEN cDNA inserts ex-
cised from dPTEN/pGEX vectors were cloned into pDEX with GFP
cDNA insert from pEGFP-C1 (Clontech). Nucleic acid sequences
were conﬁrmed by conventional sequencing methods.
2.2. Preparation of recombinant dPTEN proteins
Expression and preparation of recombinant glutathione S-transfer-
ase (GST)-fused dPTEN proteins were performed essentially as de-
scribed previously [3,16]. GST–dPTEN proteins were recovered in
elution buﬀer (50 mM Tris–HCl (pH 8), 1 mM Na-EDTA, 2 mM di-
thiothreitol, 300 mM NaCl and 10 mM glutathione), concentrated
using Centricon-30 (Amicon), and stored at )80 C until use. To de-
termine the protein concentration of GST–dPTEN proteins, protein
samples were subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE). The samples were stained with Coo-
massie brilliant blue R250 or immunoblotted with anti-GST antibody
(Cell Signalling Technology) after being transferred to FluoroTrans
membrane ﬁlter (Pall). Signals were visualized using Luminol Reagent
(Santa Cruz Biotechnology) according to the manufacturer’s recom-
mended protocol. Bovine serum albumin and GST were used as
standards for Coomassie brilliant blue R250-staining and immuno-
blotting, respectively.
2.3. Phosphatase assay
Standard assay was performed in 10 ll of the reaction mixture
consisting of 100 mM Tris–HCl (pH 8), 10 mM dithiothreitol, 0.5
mM dioleoyl phosphatidylserine (Sigma), 50 lM dipalmitoyl-
PI(3,4,5)P3, 0.2% NP-40, and 30–60 ng of GST–dPTEN protein. In
some experiments (Table 1 and Fig. 2), dipalmitoyl phosphatidylin-
ositol 3-phosphate (PI(3)P) or dipalmitoyl phosphatidylinositol 3,4-
bisphosphate (PI(3,4)P3) was used instead of PI(3,4,5)P3. All
phosphoinositides were purchased from Cayman Chemicals. After
incubation at 28 C, the amount of inorganic phosphate released
from phosphoinositides was determined as described previously [16].
2.4. Cell culture and transfection
Drosophila Schneider-2 cells (ATCC) were maintained as described
previously [17]. For the transfection, cells (1 107) were washed with
K-PBS (8.1 mM Na2HPO4, 1.46 mM KH2PO4, 30.8 mM NaCl, 120.7Table 1
Phosphatase activity of dPTEN spliced variants towards D3-phos-
phoinositides
Substrate Speciﬁc activity (nmol/min/mg)
dPTEN1 dPTEN2 dPTEN3
PI(3)P 4.4 3.3 4.5 0.5 7.1 4.8
PI(3,4)P2 72.7 3.8 92.5 16.3 72.0 4.2
PI(3,4,5)P3 136 15 669 30 583 22
Speciﬁc activity was calculated from the amount of released phosphate
from PI(3)P, PI(3,4)P2, or PI(3,4,5)P3 after 60-min, 10-min, or 3-min
incubation, respectively. All values represent means and standard
deviations from four independent determinations.mM KCl, and 10 mM MgCl2), suspended in 0.6 ml of K-PBS, and
transferred into 0.4-cm cuvette with 20 lg of plasmid DNA. After the
electroporation (500 lF, 320 V) was performed, cell suspension was
added to 4 ml of complete medium, and incubated for 2 days to allow
protein expression.
2.5. dAkt in vitro kinase assay
Cells (2 106) transfected with 5 lg of FLAG-dAkt/pDEX and 15
lg of pDEX-GFP, dPTEN1/pDEX-GFP, dPTEN2/pDEX-GFP, or
dPTEN3/pDEX-GFP were serum-starved for 2 h. After stimulating
with 10% fetal bovine serum for 15 min at 24 C, cells were lysed in 1
ml of ice-cold lysis buﬀer (50 mM Tris–HCl (pH 7.5), 120 mM NaCl,
1% NP-40, 1 mM Na-EDTA, 1 mM Na-EGTA, 25 mM NaF, 25 mM
b-glycerophosphate, 15 mM Na-pyrophosphate, 1 lM microcystin
LR, 1 mM Na-orthovanadate, 0.02% b-mercaptoethanol, 2 lg/ml of
aprotinin, 2 lg/ml of pepstatin A, 1 mM phenylmethylsulfonyl ﬂuo-
ride, and 1 mM benzamidine–HCl). After removing debris by cen-
trifugation, anti-FLAG M2 Agarose beads were added to cleared
lysate, and the mixture was incubated for 2 h at 4 C with gentle
agitation. Beads were washed with 1 ml of lysis buﬀer containing 0.5
M NaCl and 1 ml of kinase reaction buﬀer (50 mM Tris–HCl (pH
7.5) and 1 mM dithiothreitol), then 30 ll of kinase reaction buﬀer, 10
ll of myelin basic protein (2.5 mg/ml), and 10 ll of ATP solution (50
mM MgCl2, 0.25 mM ATP, and 10 lCi of [c-32P]ATP) were added to
start kinase reaction. After incubation at 30 C for 1 h, the reaction
was terminated by the addition of Laemmli sample buﬀer, then
samples were subjected to SDS–PAGE. Radioactivity incorporated
into myelin basic protein was determined by BAS1500 Bio Imaging
Analyzer (Fuji Photo Film). To analyze the expression of FLAG-
dAkt and GFP–dPTEN proteins, the transfected cells were lysed in
Laemmli sample buﬀer and immunoblotting using anti-FLAG M2
antibody (Sigma) and anti-GFP antibody (Zymed) was performed as
described in Section 2.2.
2.6. Confocal microscopy
Cells transfected with 20 lg of pDEX-GFP, dPTEN1/pDEX-GFP,
dPTEN2/pDEX-GFP, or dPTEN3/pDEX-GFP were seeded onto
glass-bottomed dishes and incubated for one day to allow cells to
attach. Fluorescence analysis was performed by confocal microscopy
(Zeiss Axiovert S100 equipped with Yokogawa confocal scanner unit
CSU21). Fluorescent intensity along major axis of the cell on captured
image was measured using NIH Image 1.62 and averaged from 10
diﬀerent images.
2.7. Analysis for the expression of dPTEN transcripts
Complementary DNA was synthesized using MoMLV reverse trans-
criptase from total RNA isolated from each developmental stage of D.
melanogaster Canton S strain. For the ampliﬁcation of dPTEN tran-
scripts, PCR (35 cycles of 94 C, 15 s; 48 C, 20 s; 68 C, 70 s+ 10 s/cycle)
was performedusing 0.5 lg of cDNAandAccuTaq polymerase (Sigma).
Primers used were TTTCGAAAGATCAGACTATGACAGTT and
TTTACAAATTCGAATAGATTAGCCAA. For the ampliﬁcation of
Act5C transcripts, PCR (25 cycles of 94 C, 30 s; 55 C, 20 s; and72 C, 45
s) was performed using 0.1 lg of cDNA and recombinant Taq poly-
merase (Takara). Primers used were CGTCTTCCCATCGATTGTG
and GATGCCAGGGTACATG- GTG. PCR products were resolved
on agarose gel and signals were visualized by ethidiumbromide staining.3. Results
3.1. Phosphoinositide phosphatase activity of dPTEN
The phosphatase domain of dPTEN is highly similar to that
of human PTEN with identity of 58% and the catalytic core
motif including two invariant lysine residues (HCKAGKGRT)
that are critical for the PI(3,4,5)P3 phosphatase activity of
human PTEN [18] is completely conserved in dPTEN. These
features strongly suggest that dPTEN functions as a
PI(3,4,5)P3 phosphatase; however, because of diﬃculty in the
preparation of recombinant dPTEN proteins, direct evidence
that dPTEN catalyzes dephosphorylation of PI(3,4,5)P3 has
Fig. 2. Eﬀect of G135E mutation on the phosphatase activity. Phos-
phatase assay for indicated D3-phosphoinositides were performed with
50 ng of GST–dPTEN2 (wild type, open column and G135 mutant,
closed column). Reactions were terminated after incubation for 30
min, then released inorganic phosphate was determined. Bars represent
diﬀerences between duplicate determinations in a typical study.
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recombinant proteins of three potential dPTEN spliced vari-
ants as GST-fusion proteins (Figs. 1A and B) and examined
their phosphatase activities towards PI(3,4,5)P3. As shown in
Fig. 1C, all spliced variants dephosphorylated PI(3,4,5)P3 and
approximately ﬁve times higher activity of dPTEN2 and
dPTEN3 than dPTEN1 was observed (Fig. 1C and Table 1).
We also tested the other D3-phosphoinositides for substrates
of dPTEN, since human PTEN utilizes PI(3,4)P2 and PI(3)P as
its substrates. PI(3,4)P2 was dephosphorylated by all spliced
variants with almost same magnitude, while PI(3)P was an
extremely poor substrate for dPTEN (Table 1).
Mutational analyses of human PTEN have revealed that the
phosphatase activity is essential for its biological function [6].
Most of tumor-associated mutations result in a loss of the
phosphatase activity. In D. melanogaster, several dPTEN
mutant alleles have been isolated ([8–10,19], and see FlyBase
FBgn0026379), and dPTENc494 encodes a missense mutant, of
which glycine-135 in the catalytic core motif was replaced by
glutamic acid (G135E) [9]. As reﬂecting absolute requirement
of the glycine residue for maintaining catalytic pocket archi-
tecture, G135E mutation resulted in complete loss of the
phosphatase activity (Fig. 2), suggesting that the phosphatase
activity is essential for dPTEN function in the Drosophila
development.
3.2. Eﬀect of dPTEN spliced variants on dAkt activity
It has been reported that dAkt is a major downstream target
of dp110/PI(3,4,5)P3 in Drosophila [11,14]. Moreover, knock
down of dPTEN by RNA interference results in signiﬁcant
enhancement of dAkt activity in Drosophila Schneider-2 cells
[17]. Although these observations clearly indicate that dPTEN
participates in PI(3,4,5)P3-dependent dAkt activation as a
negative regulator, it remains unknown which spliced form ofFig. 1. Recombinant dPTEN dephosphorylates PI(3,4,5)P3. (A)
Schematic representation of dPTEN spliced variants. (B) Recombinant
GST–dPTEN proteins (1 lg each) were subjected to SDS–PAGE,
stained by Coomassie brilliant blue R250 (Left) and immunoblotted
with anti-GST antibody (Right). (C) Time course of dPTEN-catalyzed
dephosphorylation of PI(3,4,5)P3. Reactions with each GST–dPTEN
protein (50 ng) were terminated at indicated times, then released in-
organic phosphate was determined. Bars represent diﬀerences between
duplicate determinations in a typical study.dPTEN is responsible for this signaling pathway. In order to
analyze the contribution of dPTEN spliced variants in this
signal, we overexpressed each variant with dAkt in Schneider-2
cells and assessed the eﬀects of these variants on serum-in-
duced dAkt activation (Fig. 3). In GFP-expressing control
cells, dAkt activity was increased (2.5-fold) upon serum stim-
ulation (Fig. 3B). dPTEN3 abolished the dAkt activation
completely and dPTEN1 partially suppressed the dAkt acti-
vation (Fig. 3B). Surprisingly, dPTEN2 that exhibited highest
phosphatase activity in the in vitro assay (Table 1) showed no
eﬀect on the dAkt activation (Fig. 3B), even though muchFig. 3. Suppression of serum-induced dAkt activation by dPTEN. (A)
Ectopic expression of FLAG-dAkt and GFP–dPTEN proteins were
conﬁrmed by immunoblotting with anti-FLAG antibody (top) and
anti-GFP antibody (bottom), respectively. (B) Serum-starved Schnei-
der-2 cells expressing FLAG-dAkt with either of GFP, GFP-dPTEN1,
GFP-dPTEN2, or GFP-dPTEN3 were incubated with (closed column)
or without (open column) 10% fetal bovine serum, then FLAG-dAkt
was immunoprecipitated and subjected to in vitro kinase assay.
Phosphorylation of myelin basic protein (MBP) was visualized by an
autoradiography (inset) and quantitated as described in Section 2. Bars
represent diﬀerences between duplicate determinations. Similar results
were obtained in a repeated experiment.
Fig. 4. Subcellular localization of dPTEN-spliced variants. Localization of GFP, GFP-dPTEN1, GFP-dPTEN2, and GFP-dPTEN3 proteins
expressed in Schneider-2 cells was analyzed by confocal microscopy. Represented are typical images (top) and averaged pixel intensities along the
major axis of cells (bottom).
Fig. 5. Developmental proﬁle of three dPTEN transcripts in
D. melanogaster. RT-PCR analyses were performed on RNAs isolated
from Drosophila animals of diﬀerent developmental stages as indi-
cated. PCR products corresponding to each dPTEN variants were
distinguished based on their sizes as indicated.
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served (Fig. 3A).
PI(3,4,5)P3 that activates dAkt is localized to the plasma
membranes, indicating that dPTEN must be recruited to the
plasma membranes to suppress the dAkt activation. This idea
led us to analyze intracellular localization of dPTEN variants
in Schneider-2 cells (Fig. 4). Both dPTEN1 and dPTEN3 were
predominantly localized to the plasma membranes, while
dPTEN2 was mainly localized in the cytoplasm and partially
to the plasma membrane. The dissociation of dPTEN2 from
the plasma membranes may partially account for the loss of
suppressive activity against the dAkt activation. In addition, as
dPTEN1 and dPTEN3 showed almost identical cellular lo-
calization, it is more likely that partial suppressive eﬀect of
dPTEN1 on the dAkt activation could be due to its low
PI(3,4,5)P3 phosphatase activity (Table 1).3.3. Expression of dPTEN during the Drosophila development
Genetic studies have shown that both mutation and over-
expression of dPTEN fundamentally result in embryonic le-
thality [8–11], suggesting the requirement of dPTEN and its
strictly controlled expression in the Drosophila development.
Studies described above indicate that dPTEN3 is the most
responsible spliced form for the PI(3,4,5)P3-mediated signal at
least in Schneider-2 cells. We next analyzed the expression of
dPTEN by RT-PCR with discriminating its three spliced
variant forms during the development. Either dPTEN1 or
dPTEN2, that showed small or no eﬀect on dAkt activation
(Fig. 3), was expressed evenly in each developmental stage
(Fig. 5). On the other hand, the expression of dPTEN3 was
dramatically altered during the development. In early embry-
onic stage, no expression of dPTEN3 was observed, and the
expression was increased at late embryonic stage, decreased at
pupal stage, then disappeared in adult ﬂies. Intriguingly,
dPTEN mutant ﬂies start to die at stages of late embryo and
early larva that are consistent with the time when dPTEN3
transcript appeared [9,10]. These observations, taken together,
would suggest that dPTEN3, which exhibited robust sup-
pressive activity towards the dAkt activation in Schneider-2
cells, plays a crucial role in the transition from embryos to
larvae.4. Discussion
In this study, we ﬁrst demonstrated that recombinant
dPTEN proteins dephosphorylated PI(3,4,5)P3. Its human
counterpart, PTEN, speciﬁcally hydrolyzes phosphate group
at D3 position of PI(3,4,5)P3. The speciﬁcity is determined by
highly strict coordination of the phosphate groups on the
inositol ring in the catalytic pocket [18]. Lysine-125 and lysine-
128 play critical roles in the coordination, and replacement of
these lysine residues with the neutral amino acid, methionine,
aﬀects the substrate speciﬁcity of human PTEN [18]. Methio-
nine substitution for lysine-136 (K136M) of dPTEN that is
corresponding to K128M mutation of human PTEN provided
same eﬀect as human K128M mutant does, in which
PI(3,4,5)P3 phosphatase activity was speciﬁcally eliminated
(data not shown). Moreover, dPTEN released approximately 1
mol of phosphate from 1 mol of substrate (Fig. 1C). These
results indicate that dPTEN essentially employs same catalytic
mechanism as human PTEN does. In addition, it should be
noted that dPTEN1 showed lower PI(3,4,5)P3 phosphatase
activity when compared to dPTEN2 and dPTEN3, while
PI(3,4)P2 phosphatase activity of dPTEN1 was almost identi-
cal to theirs (Table 1). The major structural diﬀerence between
dPTEN1 and dPTEN2/3 is in their extended carboxyl-terminal
regions; dPTEN1 lacks most of this region (see Fig. 1A),
T. Maehama et al. / FEBS Letters 565 (2004) 43–47 47suggesting the requirement of the carboxyl-terminal region for
the recognition of PI(3,4,5)P3 as the substrate. Another strik-
ing structural diﬀerence found in dPTEN-spliced variants is
the existence of a potential PDZ-binding motif at the carboxyl-
terminus of dPTEN2 (see Fig. 1A). Human PTEN also has a
PDZ-binding motif and several PDZ proteins are known to
bind to human PTEN through this motif [20–23]. These PDZ
proteins may recruit human PTEN to the plasma membrane
and facilitate its function as the PI(3,4,5)P3 phosphatase. In
the case of dPTEN2, its PDZ-binding motif appears to have
the opposite function, inhibiting the recruitment of dPTEN2
to the plasma membranes and its biological activity. Further
study will be required to understand the biological signiﬁcance
of the PDZ-binding motif of dPTEN2 and to identify its
binding partner(s).
Our results also have shown that dPTEN3 may be the most
responsible form in the regulation of PI(3,4,5)P3-mediated
signaling pathway in Schneider-2 cells. It has also been re-
ported that overexpression of dPTEN1 or dPTEN2 has severe
impact on Drosophila ﬂies, resulting in reduced organ size and
lethality [9,10], although these variants did not signiﬁcantly
aﬀect the dAkt activation in cultured Schneider-2 cells. These
observations raise the possibility that dPTEN1 and dPTEN2
employ unidentiﬁed activation machinery that lacks in
Schneider-2 cell to suppress dAkt-mediated signals in
Drosophila animal. It is also conceivable that dPTEN1 and
dPTEN2 are involved in the phosphoinositide-mediated but
dAkt-independent signaling process that also controls cell size
and organ size, such as Drosophila S6 kinase-mediated signals
[24,25].
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